个体化调整与固定方案利妥昔单抗维持ANCA相关性血管炎缓解的比较:多中心、随机对照、III期试验(MAINRITSAN2)结果
本研究为开放标签、多中心、随机对照III期试验,纳入诱导缓解后的GPA或MPA患者162例,比较基于每3个月生物标志物监测的个体化利妥昔单抗再输注与固定方案再输注对28个月时复发数的影响。结果显示个体化组14/81例(17.3%)复发、固定组8/81例(9.9%)复发(p=0.22),两组复发率无显著差异,个体化组输注次数更少(中位数3次 vs 5次)。
要点
- 个体化调整组与固定方案组28个月复发率无显著差异(17.3% vs 9.9%,p=0.22)。
- 个体化组累计输注248次,固定组381次,中位给药次数3次 vs 5次。
- 两组患者均接受500 mg利妥昔单抗输注,个体化组仅在CD19+B淋巴细胞或ANCA重现或ANCA滴度明显升高时再输注。
核心结论
- 个体化调整与固定方案利妥昔单抗维持方案之间,AAV复发率无显著差异。
- 个体化调整组患者接受的利妥昔单抗输注次数更少。
研究设计与样本
- 开放标签、多中心、随机对照III期试验,纳入诱导治疗后达到完全缓解的新诊断或复发性GPA或MPA患者。
- 共纳入162例患者,平均年龄60岁,女性占42%;GPA 117例(72.2%),MPA 45例(27.8%)。
- 纳入前诱导治疗:环磷酰胺100例(61.7%),利妥昔单抗61例(37.6%),甲氨蝶呤1例(0.6%)。
- 主要终点为第28个月时由独立且对治疗分组设盲的裁决委员会评估的复发数(新发或重现症状或疾病恶化且BVAS>0)。
主要发现
- 第28个月时共21例患者发生22次复发:个体化组14/81例(17.3%)发生13次复发,固定组8/81例(9.9%)发生8次复发(p=0.22)。
- 个体化组与固定组分别累计接受248次 vs 381次输注,给药次数中位数(IQR)为3(2-4)次 vs 5(5-5)次。
关键数值与推荐
- 个体化组:随机化时接受500 mg利妥昔单抗输注,此后每3个月监测,仅当CD19+B淋巴细胞或ANCA重现或ANCA滴度明显升高时再输注,直至第18个月。
- 固定方案组:随机化后第0天和第14天接受500 mg利妥昔单抗输注,首次输注后第6、12、18个月再各输注500 mg。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare individually tailored, based on trimestrial biological parameter monitoring, to fixed-schedule rituximab reinfusion for remission maintenance of antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAVs). METHODS: Patients with newly diagnosed or relapsing granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) in complete remission after induction therapy were included in an open-label, multicentre, randomised controlled trial. All tailored-arm patients received a 500 mg rituximab infusion at randomisation, with rituximab reinfusion only when CD19+B lymphocytes or ANCA had reappeared or ANCA titre rose markedly based on trimestrial testing until month 18. Controls received a fixed 500 mg rituximab infusion on days 0 and 14 postrandomisation, then 6, 12 and 18 months after the first infusion. The primary endpoint was the number of relapses (new or reappearing symptom(s) or worsening disease with Birmingham Vasculitis Activity Score (BVAS)>0) at month 28 evaluated by an independent Adjudication Committee blinded to treatment group. RESULTS: Among the 162 patients (mean age: 60 years; 42% women) included, 117 (72.2%) had GPA and 45 (27.8%) had MPA. Preinclusion induction therapy included cyclophosphamide for 100 (61.7%), rituximab for 61 (37.6%) and methotrexate for 1 (0.6%). At month 28, 21 patients had suffered 22 relapses: 14/81 (17.3%) in 13 tailored-infusion recipients and 8/81 (9.9%) in 8 fixed-schedule patients (p=0.22). The tailored-infusion versus fixed-schedule group, respectively, received 248 vs 381 infusions, with medians (IQR) of 3 (2-4) vs 5 (5-5) administrations. CONCLUSION: AAV relapse rates did not differ significantly between individually tailored and fixed-schedule rituximab regimens. Individually tailored-arm patients received fewer rituximab infusions. TRIAL REGISTRATION NUMBER: NCT01731561; Results.
引用
- Charles P, Terrier B, Perrodeau É, et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018. PMID: 29695500. doi:10.1136/annrheumdis-2017-212878
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。